Related Experiment Video

Updated: May 5, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.5K

Apathy is associated with increased amyloid burden in mild cognitive impairment

Gad A Marshall, Nancy J Donovan, Natacha Lorius

    The Journal of Neuropsychiatry and Clinical Neurosciences
    |November 20, 2013
    PubMed

    Insights

    Apathy in mild cognitive impairment (MCI) is linked to higher brain amyloid levels, as shown by PiB PET scans. This symptom was not associated with reduced brain metabolism in MCI patients.

    Area of Science:

    • Neuroscience
    • Neurology
    • Gerontology

    Background:

    • Apathy is a common symptom in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia.
    • Understanding the underlying pathology of apathy in MCI is crucial for diagnosis and treatment.

    Purpose of the Study:

    • To investigate the association between apathy and amyloid-beta (Aβ) burden in MCI.
    • To examine the relationship between apathy and regional brain metabolism in MCI.

    Main Methods:

    • Participants with MCI underwent Pittsburgh Compound B (PiB) positron emission tomography (PET) to measure cortical amyloid burden.
    • 18F-fluorodeoxyglucose (FDG) PET scans were used to assess regional brain metabolism.
    • Apathy was evaluated using the Apathy Evaluation Scale (AES).

    Main Results:

    • A significant association was found between increased apathy (lower AES scores) and greater cortical PiB retention, independent of age.
    • No significant association was observed between apathy and regional FDG metabolism in MCI patients.

    Conclusions:

    • Increased apathy in MCI is associated with a higher cortical amyloid burden.
    • Apathy in MCI may be linked to amyloid pathology rather than hypometabolism.

    More Related Videos

    Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease08:25

    Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

    Published on: April 19, 2021

    2.4K
    Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein08:27

    Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

    Published on: July 29, 2018

    13.1K

    Related Concept Videos

    Alzheimer Disease ll: Pathophysiology01:23

    Alzheimer Disease ll: Pathophysiology

    Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
    42
    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
    1.7K
    Alzheimer Disease l: Introduction01:29

    Alzheimer Disease l: Introduction

    Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
    29
    Dementia l: Introduction01:22

    Dementia l: Introduction

    Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
    35
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    1.3K
    Amyloid Fibrils03:03

    Amyloid Fibrils

    Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
    Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
    10.3K